Kleder

Lenalidomide, the active ingredient in Kleder, is an immunomodulatory agent presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma, mantle cell lymphoma and myelodysplastic syndromes in adult patients.\n\nGNH India supplies Kleder as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is used in hematologic malignancies that respond to immunomodulation and anti‑angiogenic therapy.\n\n- Multiple Myeloma: improves progression‑free survival and overall response rates in patients who have received prior therapy.\n- Mantle Cell Lymphoma: induces tumor regression and prolongs disease control in relapsed or refractory cases.\n- Myelodysplastic Syndromes: reduces transfusion dependence and delays transformation to acute leukemia in patients with del(5q) cytogenetic abnormality.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.\n\nCommon Side Effects:\n- Neutropenia\n- Thrombocytopenia\n- Fatigue\n- Nausea\n- Diarrhoea\n- Rash\n\nSerious or Rare Side Effects:\n- Venous thromboembolism\n- Severe neutropenia leading to infection\n- Secondary primary malignancies\n- Hepatotoxicity\n- Severe cutaneous reactions (Stevens‑Johnson syndrome)\n- Embryofetal toxicity (teratogenic).

Patients receiving Lenalidomide require careful monitoring and risk mitigation.\n\n- Blood Count Monitoring: perform complete blood counts regularly to detect neutropenia or thrombocytopenia.\n- Thromboembolic Risk Assessment: evaluate for clotting risk and consider prophylactic anticoagulation when appropriate.\n- Pregnancy Prevention: enforce strict contraception for both male and female patients of reproductive potential.\n- Renal Function Adjustment: dose may need modification in patients with impaired renal clearance.\n- Drug Interaction Review: avoid concomitant use with known contraindicated agents.\n- Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide can interact with several drug classes, requiring vigilance.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) – may increase exposure.\n- Thalidomide – combined use heightens risk of severe peripheral neuropathy and thromboembolism.\n- Live vaccines – immunosuppression can reduce vaccine efficacy and increase infection risk.\n\nModerate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine) – may reduce therapeutic levels.\n- NSAIDs – may increase risk of renal impairment when combined with Lenalidomide.\n- CYP2C19 inhibitors (e.g., fluoxetine) – may modestly raise plasma concentrations.